NewsBenzingaAclaris 抗 TSLP 抗体 Bosakitug 治疗特应性皮炎的 ADMIRATION 二期试验未达到 24 周 EASI 变化百分比这一主要终点,次要终点也未达成 Aclaris 抗 TSLP 抗体 Bosakitug 治疗特应性皮炎的 ADMIRATION 二期试验未达到 24 周 EASI 变化百分比这一主要终点,次要终点也未达成 Benzinga 2026.11.16 08:34 (GMT+0) Open on Benzinga Other news GlobalFoundries to Test Atlas Humanoids in Early 2027 Coinbase Account Connection Opens to All ChatGPT Users NVIDIA Earnings Preview: Management Transition and Whether Q4 Revenue Guidance Can Break Through $125 Billion Nvidia’s first big move after Jensen Huang’s exit targets national security Bitwise Launches AI Cybersecurity ETF ZDAY, Focusing on Companies Defending Against AI Attacks and Securing AI Systems Michael Burry Is Betting on an AI Stock Selloff. I’d Rather Buy the Dip.
NVIDIA Earnings Preview: Management Transition and Whether Q4 Revenue Guidance Can Break Through $125 Billion
Bitwise Launches AI Cybersecurity ETF ZDAY, Focusing on Companies Defending Against AI Attacks and Securing AI Systems